Skip to Content

4,309 Results Found

  • Review
  • Open Access
55 Citations
6,384 Views
26 Pages

Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy

  • Chiara Cremolini,
  • Emanuela Vitale,
  • Raffaella Rastaldo and
  • Claudia Giachino

Immune checkpoint receptor signaling pathways constitute a prominent class of “immune synapse,” a cell-to-cell connection that represses T-lymphocyte effector functions. As a possible evolutionary countermeasure against autoimmunity, this strategy is...

(This article belongs to the Section Biology and Medicines)
  • Review
  • Open Access
17 Citations
5,501 Views
28 Pages

Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers

  • Tobias Ettl,
  • Matthias Grube,
  • Daniela Schulz and
  • Richard Josef Bauer

11 October 2022

Recently, considerable progress has been achieved in cancer immunotherapy. Targeted immune checkpoint therapies have been established for several forms of cancers, which resulted in a tremendous positive impact on patient survival, even in more advan...

(This article belongs to the Special Issue Immune Checkpoint Inhibitors in Cancer Therapy—How Can We Improve Clinical Benefits?)
  • Review
  • Open Access
21 Citations
4,702 Views
18 Pages

Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma

  • Yasuyuki Tamai,
  • Naoto Fujiwara,
  • Takamitsu Tanaka,
  • Shugo Mizuno and
  • Hayato Nakagawa

20 October 2023

Hepatocellular carcinoma (HCC) is estimated to be the fourth leading cause of cancer-related deaths globally, and its overall prognosis is dismal because most cases are diagnosed at a late stage and are unamenable to curative treatment. The emergence...

(This article belongs to the Special Issue Systemic Therapy for Hepatocellular Carcinoma)
  • Review
  • Open Access
42 Citations
6,217 Views
17 Pages

Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation

  • Nitin N. Katariya,
  • Blanca C. Lizaola-Mayo,
  • David M. Chascsa,
  • Emmanouil Giorgakis and ,
  • Bashar A. Aqel,
  • Adyr A. Moss,
  • Pedro Luiz Serrano Uson Junior,
  • Mitesh J. Borad and
  • Amit K. Mathur
  • + 4 authors+ 0 author

19 April 2022

Hepatocellular Carcinoma (HCC) is the most common liver malignancy and third leading cause of cancer death worldwide. For early- and intermediate-stage disease, liver-directed therapies for locoregional control, or down-staging prior to definitive su...

(This article belongs to the Special Issue Immune Checkpoint and Novel Perspectives in the Management of Hepatocellular Carcinoma)
  • Article
  • Open Access
20 Citations
3,621 Views
20 Pages

Pheophorbide A–Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD–L1 Expression

  • Qinli Tong,
  • Jiaojiao Xu,
  • Aihua Wu,
  • Chen Zhang and ,
  • Afeng Yang,
  • Sihang Zhang,
  • Hongzheng Lin and
  • Wei Lu
  • + 3 authors+ 0 author

Although the immune checkpoint blockade (ICB) has made a great success in cancer immunotherapy, the overall response rate to the ICB, such as anti–programmed death ligand 1 (PD–L1) therapy, remains only at 20–30%. One major reason i...

  • Review
  • Open Access
20 Citations
6,026 Views
20 Pages

Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma

  • Perla Chami,
  • Youssef Diab,
  • Danny N. Khalil,
  • Hassan Azhari and ,
  • William R. Jarnagin,
  • Ghassan K. Abou-Alfa,
  • James J. Harding,
  • Joseph Hajj,
  • Jennifer Ma and
  • Carla Hajj
  • + 8 authors+ 3 authors

26 November 2023

The liver tumor immune microenvironment has been thought to possess a critical role in the development and progression of hepatocellular carcinoma (HCC). Despite the approval of immune checkpoint inhibitors (ICIs), such as programmed cell death recep...

(This article belongs to the Special Issue Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy)
  • Review
  • Open Access
13 Citations
5,960 Views
19 Pages

Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy

  • Vanina Vani,
  • Daniele Regge,
  • Giovanni Cappello,
  • Michela Gabelloni and
  • Emanuele Neri

Immunotherapy with checkpoint inhibitors (ICIs) is becoming standard of practice for an increasing number of cancer types. ICIs enhance T-cell action against the cancer cells. By unbalancing the immune system ICIs may cause dysimmune toxicities, a se...

(This article belongs to the Section Medical Imaging and Theranostics)
  • Opinion
  • Open Access
3 Citations
2,750 Views
9 Pages

3 June 2024

Classic Hodgkin lymphoma (cHL) is a B-cell lymphoma in which tumour cells, the so-called Hodgkin Reed–Sternberg (HRS) cells, are admixed with non-malignant cell types that are a functional part of the disease. Immune cells, fibroblasts, special...

(This article belongs to the Section Lymphomas)
  • Article
  • Open Access
16 Citations
5,754 Views
13 Pages

25 April 2022

Targeted therapy in combination with immune checkpoint inhibitors has been recently implemented in advanced or metastatic renal cancer treatment. However, many treated patients either do not respond or develop resistance to therapy, making alternativ...

(This article belongs to the Section Cellular Pathology)
  • Article
  • Open Access
9 Citations
3,734 Views
17 Pages

Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000–2016

  • Peter Hellmund,
  • Jochen Schmitt,
  • Martin Roessler,
  • Friedegund Meier and
  • Olaf Schoffer

20 August 2020

Targeted therapies (TT) and immune checkpoint inhibitors (ICI) have become increasingly important in the treatment of metastatic malignant melanoma in recent years. We examined implementation and effectiveness of these new therapies over time in Germ...

(This article belongs to the Special Issue Targeted Therapies for Melanoma)
  • Review
  • Open Access
11 Citations
4,487 Views
17 Pages

27 May 2023

Malignant pleural mesothelioma (MPM) is a malignancy associated with asbestos exposure and is typically categorized as an orphan disease. Recent developments in immunotherapy with anti-PD-1 and anti-CTLA-4 antibodies, specifically with agents nivolum...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Review
  • Open Access
22 Citations
5,664 Views
43 Pages

Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer

  • Gian Marco Leone,
  • Saverio Candido,
  • Alessandro Lavoro,
  • Silvia Vivarelli and ,
  • Giuseppe Gattuso,
  • Daniela Calina,
  • Massimo Libra and
  • Luca Falzone
  • + 3 authors+ 0 author

Lung cancer (LC) represents the second most diagnosed tumor and the malignancy with the highest mortality rate. In recent years, tremendous progress has been made in the treatment of this tumor thanks to the discovery, testing, and clinical approval...

(This article belongs to the Special Issue Novel Anticancer Strategies, 3rd Edition)
  • Review
  • Open Access
24 Citations
8,720 Views
14 Pages

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors

  • Junichi Soh,
  • Akira Hamada,
  • Toshio Fujino and
  • Tetsuya Mitsudomi

10 August 2021

The emergence of immune checkpoint inhibitors (ICIs) has dramatically changed the treatment landscape for patients with metastatic non-small cell lung cancer (NSCLC). These achievements inspired investigators and pharmaceutical companies to conduct c...

(This article belongs to the Special Issue Surgical Treatment of Lung Cancer)
  • Review
  • Open Access
93 Citations
12,957 Views
20 Pages

22 May 2023

Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape of cancer and have been widely approved for use in the treatment of diverse solid tumors. Targeted therapy has been an essential part of cancer treatment for decades, a...

(This article belongs to the Special Issue Advances in Cancer Immunotherapy)
  • Feature Paper
  • Review
  • Open Access
11 Citations
7,527 Views
32 Pages

Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH

  • Sunil Kumar,
  • Parth Sarthi,
  • Indra Mani,
  • Muhammad Umer Ashraf and ,
  • Myeong-Ho Kang,
  • Vishal Kumar and
  • Yong-Soo Bae
  • + 2 authors+ 0 author

30 August 2021

Cellular immunotherapy has recently emerged as a fourth pillar in cancer treatment co-joining surgery, chemotherapy and radiotherapy. Where, the discovery of immune checkpoint blockage or inhibition (ICB/ICI), anti-PD-1/PD-L1 and anti-CTLA4-based, th...

(This article belongs to the Special Issue 10th Anniversary of Cells—Advances in Cellular Immunology)
  • Review
  • Open Access
15 Citations
9,712 Views
12 Pages

Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy

  • Kasper F. Guldbrandsen,
  • Helle W. Hendel,
  • Seppo W. Langer and
  • Barbara M. Fischer

Immune checkpoint inhibitor therapy (ICT) is a new treatment strategy developed for the treatment of cancer. ICT inhibits pathways known to downregulate the innate immune response to cancer cells. These drugs have been shown to be effective in the tr...

(This article belongs to the Special Issue Imaging of Early Response in Cancer Management)
  • Review
  • Open Access
10 Citations
5,325 Views
16 Pages

The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients

  • Alessandro Allegra,
  • Eleonora Di Salvo,
  • Marco Casciaro,
  • Caterina Musolino and ,
  • Giovanni Pioggia and
  • Sebastiano Gangemi
  • + 1 author+ 0 author

Although pruritus may sometimes be a consequential situation to neoplasms, it more frequently emerges after commencing chemotherapy. In this review, we present our analysis of the chemotherapy treatments that most often induce skin changes and itchin...

(This article belongs to the Section Immunology and Immunotherapy)
  • Review
  • Open Access
63 Citations
8,798 Views
11 Pages

13 October 2017

Therapeutic resistance remains a major obstacle in treating many cancers, particularly in advanced stages. It is likely that cytotoxic lymphocytes (CTLs) have the potential to eliminate therapy-resistant cancer cells. However, their effectiveness may...

(This article belongs to the Special Issue Angiogenesis and Anti-Angiogenesis in Oncology: From Bench to Translational Research and Bedside Investigation)
  • Review
  • Open Access
27 Citations
6,921 Views
18 Pages

There has been significant progress in immune checkpoint inhibitor (CPI) therapy in many solid tumor types. However, only a single failed study has been published in treating Ph(-) myeloproliferative neoplasm (MPN). To make progress in CPI studies on...

(This article belongs to the Special Issue PD-L1, a Master Regulator of Immunity 2.0)
  • Feature Paper
  • Article
  • Open Access
10 Citations
5,281 Views
18 Pages

Minibeam Spatially-Fractionated Radiation Therapy Is Superior to Uniform Dose Radiation Therapy for Abscopal Effect When Combined with PD-L1 Checkpoint Inhibitor Immunotherapy in a Dual Tumor Murine Mammary Carcinoma Model

  • Judith N. Rivera,
  • Keith Laemont,
  • Artak Tovmasyan,
  • Stefan Stryker and ,
  • Kenneth Young,
  • Theresa Charity,
  • Gregory M. Palmer and
  • Sha Chang
  • + 3 authors+ 0 author

Spatially fractionated radiation therapy (SFRT) has a long history of treating bulky and hypoxic tumors. Recent evidence suggests that, compared to conventional uniform dose radiation therapy, SFRT may utilize different mechanisms of tumor cell killi...

  • Opinion
  • Open Access
7 Citations
3,550 Views
12 Pages

14 September 2023

Longitudinal strain (LS) measured by echocardiography has been reported to be useful not only for the diagnosis and risk stratification of various cardiac diseases, but also in cardio-oncology. Most previous studies have been conducted on patients un...

(This article belongs to the Special Issue Immune-Related Adverse Effects of Checkpoint Inhibitors in Cancer Patients)
  • Article
  • Open Access
11 Citations
3,909 Views
16 Pages

We describe an innovative approach for identification of tolerance breakage during immune checkpoint inhibitor therapy in malignant melanoma. Checkpoint inhibitor therapy enhances the immunologic clearance of cancer by suppressing pathways which indu...

(This article belongs to the Special Issue Cancer Immunoediting and Beyond)
  • Review
  • Open Access
14 Citations
7,552 Views
48 Pages

Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy

  • Ruth Christine Winter,
  • Mariam Amghar,
  • Anja S. Wacker,
  • Gábor Bakos and ,
  • Harun Taş,
  • Mareike Roscher,
  • James M. Kelly and
  • Martina Benešová-Schäfer
  • + 3 authors+ 0 author

5 August 2024

Cancer is one of the most complex and challenging human diseases, with rising incidences and cancer-related deaths despite improved diagnosis and personalized treatment options. Targeted alpha therapy (TαT) offers an exciting strategy emerging...

(This article belongs to the Special Issue Advances in Pharmaceutical Sciences: In Honor of Dr. Jean Jacques Vanden Eynde (JJ))
  • Article
  • Open Access
3 Citations
1,461 Views
18 Pages

Photothermal Therapy-Induced Immunogenic Cell Death Synergistically Enhances the Therapeutic Effect of Immune Checkpoint Inhibitors

  • Shogo Yasuda,
  • Yui Horikawa,
  • Mei Ohashi,
  • Mai Amou and ,
  • Taisei Kanamori,
  • Duan Runjing,
  • Yuta Tamemoto,
  • Wei Xu,
  • Takuro Niidome and
  • Hiroto Hatakeyama
  • + 6 authors+ 1 author

16 January 2026

Background/Objectives: To improve the response rate of immune checkpoint inhibitors (ICIs), inducing immunogenic cell death (ICD) is a promising approach. Photothermal therapy (PTT) induces immunogenic cell death and activates anti-tumor immunity. Wh...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Article
  • Open Access
2,980 Views
22 Pages

Radionuclide-Dependent Stimulation of Antitumor Immunity in GD2-Targeted Radiopharmaceutical Therapy Combined with Immune Checkpoint Inhibitors

  • Cynthia Lilieholm,
  • Jen Zaborek,
  • Ohyun Kwon,
  • Adedamola O. Adeniyi and ,
  • Caroline P. Kerr,
  • Hansel Comas Rojas,
  • Malick Bio Idrissou,
  • Carolina A. Ferreira,
  • Paul A. Clark and
  • Jamey P. Weichert
  • + 15 authors+ 10 authors

9 December 2025

Radiopharmaceutical therapy (RPT) offers tumor-selective radiation delivery and represents a promising platform for combination with immune checkpoint inhibitors (ICIs). While prior studies suggest that RPT can stimulate antitumor immunity, synergy w...

  • Article
  • Open Access
1 Citations
1,879 Views
17 Pages

Medulloblastoma (MB) is one of the most common malignant pediatric brain tumors. Current therapy results in a poor prognosis for high-risk SHH/p53-mutated MB, emphasizing the importance of more effective therapeutic strategies. Here, we investigated...

(This article belongs to the Section Molecular Oncology)
  • Review
  • Open Access
5 Citations
2,387 Views
11 Pages

11 February 2025

The treatment landscape of pancreatic ductal adenocarcinoma (PDAC) has seen slow progress, with immune-checkpoint inhibitors (ICIs) failing to replicate the success observed in other malignancies. The immune-suppressive tumor microenvironment (TME) i...

(This article belongs to the Special Issue Clinical Trials for Hepatobiliary and Pancreatic Cancer Diagnosis and Treatment)
  • Review
  • Open Access
14 Citations
4,657 Views
22 Pages

The Role of Immune Checkpoints after Cellular Therapy

  • Friederike Schmitz,
  • Dominik Wolf and
  • Tobias A.W. Holderried

Cellular therapies utilize the powerful force of the human immune system to target malignant cells. Allogeneic hematopoietic stem cell transplantation (allo-HCT) is the most established cellular therapy, but chimeric antigen receptor (CAR) T cell the...

(This article belongs to the Special Issue Microenvironment in Cancer Progression and Metastases: Crosstalk between Cancer Cells and Microenvironment)
  • Review
  • Open Access
25 Citations
6,133 Views
15 Pages

Immune Escape in Glioblastoma: Mechanisms of Action and Implications for Immune Checkpoint Inhibitors and CAR T-Cell Therapy

  • Catherine Yu,
  • Kristin Hsieh,
  • Daniel R. Cherry,
  • Anthony D. Nehlsen and ,
  • Lucas Resende Salgado,
  • Stanislav Lazarev and
  • Kunal K. Sindhu
  • + 2 authors+ 0 author

15 December 2023

Glioblastoma, the most common primary brain cancer in adults, is characterized by a poor prognosis and resistance to standard treatments. The advent of immunotherapy has revolutionized the treatment of several cancers in recent years but has failed t...

(This article belongs to the Special Issue Progression of the Immune Escape Mechanism in Tumors)
  • Article
  • Open Access
7 Citations
2,369 Views
11 Pages

Immune Checkpoint Inhibitors after Radiation Therapy Improve Overall Survival Rates in Patients with Stage IV Lung Cancer

  • Hidekazu Tanaka,
  • Kazushi Ueda,
  • Masako Karita,
  • Taiki Ono and ,
  • Yuki Manabe,
  • Miki Kajima,
  • Koya Fujimoto,
  • Yuki Yuasa and
  • Takehiro Shiinoki
  • + 4 authors+ 0 author

25 August 2023

This exploratory and retrospective study aimed to evaluate whether there is a difference in the overall survival (OS) rates of patients with stage IV lung cancer who underwent radiation therapy (RT) depending on the presence or absence of immune chec...

(This article belongs to the Special Issue Advances in Modern Radiation Oncology)
  • Article
  • Open Access
29 Citations
7,851 Views
12 Pages

Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identifies Immune Checkpoint Inhibitor Therapy-Related Pneumonitis

  • Carlo Augusto Mallio,
  • Andrea Napolitano,
  • Gennaro Castiello,
  • Francesco Maria Giordano and ,
  • Pasquale D'Alessio,
  • Mario Iozzino,
  • Yipeng Sun,
  • Silvia Angeletti,
  • Marco Russano and
  • Carlo Cosimo Quattrocchi
  • + 9 authors+ 4 authors

6 February 2021

Background: Coronavirus disease 2019 (COVID-19) pneumonia and immune checkpoint inhibitor (ICI) therapy-related pneumonitis share common features. The aim of this study was to determine on chest computed tomography (CT) images whether a deep convolut...

(This article belongs to the Special Issue Radiology and Imaging of Cancer)
  • Review
  • Open Access
30 Citations
6,956 Views
13 Pages

22 December 2022

The combination of stereotactic body radiation therapy (SBRT) plus immune checkpoint inhibitors (ICI) must be explored to treat advanced primary liver tumors such as hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Limited retrospective r...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Review
  • Open Access
42 Citations
11,761 Views
41 Pages

11 July 2022

In the past 25 years, a considerable number of therapeutic monoclonal antibodies (mAb) against a variety of tumor-associated antigens (TAA) have become available for the targeted treatment of hematologic and solid cancers. Such antibodies opsonize ca...

(This article belongs to the Special Issue Tumor-Associated Myeloid Cells)
  • Systematic Review
  • Open Access
10 Citations
3,418 Views
13 Pages

20 July 2024

Introduction: There is a significant gap in the literature concerning the effective management of second-line therapy for patients with metastatic renal cell carcinoma (RCC) who have received immune checkpoint inhibitors (ICIs). Most of the published...

(This article belongs to the Special Issue Advances in Drug Delivery for Cancer Therapy)
  • Article
  • Open Access
9 Citations
2,446 Views
13 Pages

Adjuvant Therapy with Immune Checkpoint Inhibitors after Carbon Ion Radiotherapy for Mucosal Melanoma of the Head and Neck: A Case-Control Study

  • Nobutaka Mizoguchi,
  • Kio Kano,
  • Tatsuya Okuda,
  • Hiroaki Koge and ,
  • Satoshi Shima,
  • Keisuke Tsuchida,
  • Yosuke Takakusagi,
  • Shohei Kawashiro,
  • Manatsu Yoshida and
  • Hiroyuki Katoh
  • + 11 authors+ 6 authors

23 July 2024

The development of new treatment strategies to improve the prognosis of mucosal malignant melanoma of the head and neck (MMHN) after carbon ion radiotherapy (CIRT) is essential because of the risk of distant metastases. Therefore, our objective was t...

(This article belongs to the Special Issue Advances in Radiotherapy for Head and Neck Cancer)
  • Article
  • Open Access
930 Views
13 Pages

Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis

  • Lili Zhang,
  • Ayrton Bangolo,
  • Behzad Amoozgar,
  • Sarvarinder Gill and ,
  • Jiahe Zhao,
  • Gurpavitar Singh Bhullar,
  • Sindhu Singareddy,
  • Shubhangi Singh,
  • Henry Ortiz and
  • Noa Biran
  • + 25 authors+ 20 authors

19 June 2026

Background/Objectives: Extramedullary disease (EMD) is an aggressive and treatment-resistant manifestation of multiple myeloma with limited therapeutic options, particularly in heavily pretreated patients. Methods: We conducted a retrospective study...

(This article belongs to the Special Issue Image-Guided Adaptive Radiation Therapy (IGART): Advancing Precision Oncology)
  • Article
  • Open Access
10 Citations
2,955 Views
10 Pages

Enhancement of Radiation Therapy through Blockade of the Immune Checkpoint, V-domain Ig Suppressor of T Cell Activation (VISTA), in Melanoma and Adenocarcinoma Murine Models

  • Kayla E. A. Duval,
  • Armin D. Tavakkoli,
  • Alireza Kheirollah,
  • Haille E. Soderholm and ,
  • Eugene Demidenko,
  • Janet L. Lines,
  • Walburga Croteau,
  • Samuel C. Zhang,
  • Robert J. Wagner and
  • P. Jack Hoopes
  • + 7 authors+ 2 authors

6 September 2023

Radiation therapy (RT) has recently demonstrated promise at stimulating an enhanced immune response. The recent success of immunotherapies, such as checkpoint inhibitors, CART cells, and other immune modulators, affords new opportunities for combinat...

(This article belongs to the Special Issue Radiation as a Double-Edged Sword: Cancer Therapy and Potential Harm)
  • Article
  • Open Access
16 Citations
4,077 Views
12 Pages

Cancer Therapy-Related Cardiac Dysfunction in Patients Treated with a Combination of an Immune Checkpoint Inhibitor and Doxorubicin

  • Seon-Hwa Lee,
  • Iksung Cho,
  • Seng-Chan You,
  • Min-Jae Cha and ,
  • Jee-Suk Chang,
  • William D. Kim,
  • Kyu-yong Go,
  • Dae-Young Kim,
  • Jiwon Seo and
  • Hyo-Song Kim
  • + 10 authors+ 5 authors

7 May 2022

Backgrounds: There are scarce data on whether immune checkpoint inhibitors (ICIs) increase the risk of cardiac dysfunction when used with cardiotoxic agents. Thus, we evaluated cardiac dysfunction in patients with sarcoma receiving doxorubicin with o...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Article
  • Open Access
35 Citations
3,810 Views
12 Pages

17 March 2021

Introduction: In the current study, we aimed to assess the impact of antibiotics (ATB) and metabolic parameters on clinical outcome of non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI). Methods: Data from...

(This article belongs to the Special Issue Cancer Management in the Era of Immunotherapy)
  • Feature Paper
  • Article
  • Open Access
35 Citations
5,406 Views
11 Pages

Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?

  • Maartje G. Schouwenburg,
  • Karijn P.M. Suijkerbuijk,
  • Rutger H.T. Koornstra,
  • Anouk Jochems and ,
  • Michiel C.T. van Zeijl,
  • Alfons J.M. van den Eertwegh,
  • John B.A.G. Haanen,
  • Maureen J.B. Aarts,
  • Alexander C.J. van Akkooi and
  • Michel W.J.M. Wouters
  • + 15 authors+ 10 authors

4 December 2019

The prognosis of patients with advanced melanoma has improved dramatically. However, the clinical outcomes of patients with highly elevated serum lactate dehydrogenase (LDH) remain very poor. The aim of this study was to explore whether patients with...

(This article belongs to the Special Issue Advanced Melanoma)
  • Review
  • Open Access
9 Citations
4,146 Views
14 Pages

27 June 2022

Stereotactic body radiation therapy (SBRT) has been widely adopted as an alternative to lobar resection in medically inoperable patients with lymph-node negative (N0) early-stage (ES) non-small cell lung cancer (NSCLC). Excellent in-field local contr...

(This article belongs to the Special Issue Immunotherapy for Non-small Cell Lung Cancer)
  • Review
  • Open Access
35 Citations
10,020 Views
30 Pages

Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors and CAR-T Cell Therapy: A Comprehensive Imaging-Based Review

  • Chiara Pozzessere,
  • Bianca Mazini,
  • Patrick Omoumi,
  • Mario Jreige and ,
  • Leslie Noirez,
  • Antonia Digklia,
  • François Fasquelle,
  • Christine Sempoux and
  • Clarisse Dromain
  • + 4 authors+ 0 author

19 July 2024

Immunotherapy has revolutionized oncology care, improving patient outcomes in several cancers. However, these therapies are also associated with typical immune-related adverse events due to the enhanced inflammatory and immune response. These toxicit...

(This article belongs to the Special Issue How to Properly Diagnose and Treat Immune-Related Adverse Events during Immunotherapy in Patients with Cancer: Discussion between Specialists)
  • Systematic Review
  • Open Access
10 Citations
4,961 Views
22 Pages

26 June 2021

Background: In the first and second-line therapy of metastatic urothelial carcinoma (mUC), checkpoint inhibitors (CPI) such as Pembrolizumab and Atezolizumab have been widely implemented. Little is currently known about what therapeutic options are e...

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
13 Citations
5,021 Views
14 Pages

Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

  • Philip Young,
  • Omar Elghawy,
  • Joseph Mock,
  • Emmett Wynter and ,
  • Ryan D. Gentzler,
  • Linda W. Martin,
  • Wendy Novicoff and
  • Richard Hall
  • + 3 authors+ 0 author

3 January 2024

Immune checkpoint inhibitors (ICI) have significantly improved outcomes in advanced non-small cell lung cancer (NSCLC). We evaluated the effect of opioid use on outcomes in patients receiving ICI either alone or with chemotherapy. We conducted a retr...

(This article belongs to the Section Thoracic Oncology)
  • Article
  • Open Access
28 Citations
3,432 Views
10 Pages

25 July 2022

Background: This study compared the effectiveness of the combined administration of sorafenib, an immune checkpoint inhibitor, transcatheter arterial chemoembolization (TACE), and stereotactic body radiation therapy (SBRT) (SITS group) vs. sorafenib...

  • Systematic Review
  • Open Access
21 Citations
6,079 Views
21 Pages

From Interferon to Checkpoint Inhibition Therapy—A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette–Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC)

  • Susanne Deininger,
  • Peter Törzsök,
  • Michael Mitterberger,
  • Maximilian Pallauf and ,
  • David Oswald,
  • Christian Deininger and
  • Lukas Lusuardi
  • + 2 authors+ 0 author

29 January 2022

Background: In Bacillus Calmette–Guérin (BCG) refractory non-muscle-invasive bladder cancer (NMIBC), radical cystectomy is the gold standard. The advent of immune checkpoint inhibitors (CPIs) has permanently changed the therapy landscape...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Case Report
  • Open Access
38 Citations
6,579 Views
10 Pages

Pembrolizumab is an immune checkpoint inhibitor (ICI), currently recommended as the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) showing ≥50% expression of programmed death-ligand 1 (PD-L1). Previously it was...

(This article belongs to the Special Issue PD-L1, A Master Regulator of Immunity)
  • Systematic Review
  • Open Access
1 Citations
1,836 Views
11 Pages

Salvage Pulmonary Resection After Immune Checkpoint or Tyrosine Kinase Inhibitor Therapy for Initially Unresectable Non-Small-Cell Lung Cancer: A Systematic Review

  • Vasile Gaborean,
  • Catalin Vladut Ionut Feier,
  • Razvan Constantin Vonica,
  • Alaviana Monique Faur and ,
  • Vladut Iosif Rus and
  • Calin Muntean
  • + 1 author+ 0 author

Background and Objectives: Systemic conversion of stage III–IV non-small-cell lung cancer (NSCLC) to a surgically resectable state with immune checkpoint inhibitors (ICIs) or tyrosine kinase inhibitors (TKIs) creates an emerging cohort of candi...

(This article belongs to the Special Issue Emerging Insights in Thoracic Diseases: From Diagnostics to Biomarkers and Therapeutic Implications Through Interdisciplinarity)
  • Review
  • Open Access
42 Citations
4,748 Views
15 Pages

Immune-Checkpoint Blockade Therapy in Lymphoma

  • Ayumi Kuzume,
  • SungGi Chi,
  • Nobuhiko Yamauchi and
  • Yosuke Minami

Tumor cells use immune-checkpoint pathways to evade the host immune system and suppress immune cell function. These cells express programmed cell-death protein 1 ligand 1 (PD-L1)/PD-L2, which bind to the programmed cell-death protein 1 (PD-1) present...

(This article belongs to the Special Issue Novel Approaches to Hematologic Malignancies by Immunotherapy)
  • Review
  • Open Access
86 Citations
12,977 Views
33 Pages

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy

  • Juwon Lee,
  • Youngjin Han,
  • Wenyu Wang,
  • HyunA Jo and ,
  • Heeyeon Kim,
  • Soochi Kim,
  • Kyung-Min Yang,
  • Seong-Jin Kim,
  • Danny N. Dhanasekaran and
  • Yong Sang Song
  • + 5 authors+ 0 author

27 July 2021

The interaction of immune checkpoint molecules in the tumor microenvironment reduces the anti-tumor immune response by suppressing the recognition of T cells to tumor cells. Immune checkpoint inhibitor (ICI) therapy is emerging as a promising therape...

(This article belongs to the Section Molecular Medicine)

of 87